+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07726888

Real-World Evaluation of Guselkumab for Moderate-to-Severe Ulcerative Colitis Safety and Effectiveness

Led by Second Affiliated Hospital of Wenzhou Medical University · Updated on 2026-10-20

97

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the clinical efficacy and safety of guselkumab in treating patients with moderate-to-severe ulcerative colitis. This real-world prospective cohort study examines multiple outcomes, including clinical, biochemical, and endoscopic remission, as well as histologic healing and intestinal ultrasound changes. Participants receive an initial intravenous guselkumab induction therapy of 200 mg at weeks 0, 4, and 8. At week 12, based on clinical assessments, patients either continue with 100 mg subcutaneous injections every 8 weeks or increase to 200 mg every 4 weeks as maintenance. At week 24, patients achieving endoscopic remission switch to 100 mg every 8 weeks, while others continue the 200 mg every 4 weeks regimen. Throughout the study, participants undergo evaluations including symptom scoring, endoscopic and biochemical assessments, and intestinal ultrasound. Key outcomes measured are endoscopic and histologic remission at 48 weeks, clinical and biochemical remission at 12 weeks, and drug persistence rates. Safety and hospitalization rates are also monitored, with the study lasting up to 48 weeks of follow-up.

CONDITIONS

Brief Title

Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis

Research Team

Y

Yi Jiang, Doctor of Medicine

G

guolong Ma, Master of Medicine

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here